GH Research PLC - ESG Rating & Company Profile powered by AI
This SDG assessment for GH Research PLC represents its transparency towards the United Nations Sustainable Development Goals. This analysis of GH Research PLC is prepared by All Street Sevva using proprietary machine learning. Browse to the end of this page for potential risks for GH Research PLC based on industry, location and size.
GH Research PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | GH Research PLC | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does GH Research PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes GH Research PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes GH Research PLC report the average age of the workforce?
Sign up for free to unlockDoes GH Research PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes GH Research PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes GH Research PLC disclose cybersecurity risks?
Sign up for free to unlockDoes GH Research PLC offer flexible work?
Sign up for free to unlockDoes GH Research PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes GH Research PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes GH Research PLC conduct supply chain audits?
Sign up for free to unlockDoes GH Research PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes GH Research PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes GH Research PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes GH Research PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes GH Research PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes GH Research PLC disclose water use targets?
Sign up for free to unlockDoes GH Research PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid GH Research PLC have a product recall in the last two years?
Sign up for free to unlockDoes GH Research PLC disclose incidents of discrimination?
Sign up for free to unlockDoes GH Research PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas GH Research PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes GH Research PLC disclose parental leave metrics?
Sign up for free to unlockDoes GH Research PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes GH Research PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes GH Research PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes GH Research PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes GH Research PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes GH Research PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs GH Research PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes GH Research PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes GH Research PLC disclose its waste policy?
Sign up for free to unlockDoes GH Research PLC report according to TCFD requirements?
Sign up for free to unlockDoes GH Research PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes GH Research PLC disclose energy use targets?
Sign up for free to unlockDoes GH Research PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes GH Research PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for GH Research PLC
These potential risks are based on the size, segment and geographies of the company.
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.